Nandro F 150 – Nandrolone Phenylpropionate
Nandro F 150 by Royal Pharmaceuticals contains nandrolone phenylpropionate 150 mg/ml, a short-to-medium acting 19-nor anabolic steroid commonly used in laboratory research on nitrogen retention, muscle protein synthesis, bone-density pathways, and endocrine suppression models. Supplied strictly for research use only; not for human or veterinary application.
€ 49.00
Beschreibung
Nandro F 150 – Nandrolone Phenylpropionate (Royal Pharmaceuticals)
Category: Injectable Anabolic Steroid (Research Only)
Brand: Königliche Pharmazeutika
Content: 150 mg/ml nandrolone phenylpropionate (NPP)
Packaging: 10 × 1 ml ampoules (total 1,500 mg active)
Origin: United Kingdom
Price: €49
Use Notice: For laboratory / analytical research only. Not for human or veterinary use.
🧪 Scientific Overview
Nandro F 150 contains nandrolone phenylpropionate (NPP), a short/medium-acting ester of nandrolone.
Nandrolone is a 19-nor testosterone derivative with a strong anabolic profile and moderate androgenic activity in laboratory models.
NPP’s faster ester kinetics make it suitable for experiments requiring tighter timing, repeated exposures, or controlled pharmacokinetic curves compared with long esters like decanoate.
This compound is widely used in research on muscle protein metabolism, nitrogen balance, bone density, connective-tissue repair, and endocrine suppression.
Nandrolone and all its esters are prohibited anabolic agents under WADA rules.
🔬 Key Research Details
- Compound Type: Anabolic–androgenic steroid (19-nor testosterone derivative)
- Ester: Phenylpropionate — short/medium half-life
- Strength: 150 mg/ml
- Form: Oil-based injectable for IM research use
- Laboratory Research Themes:
- Anabolic vs. androgenic signaling
- Nitrogen retention & protein turnover
- Muscle mass, strength, and anabolic modeling
- Bone mineral density & collagen synthesis
- Endocrine suppression & HPG-axis studies
- Short-acting AAS pharmacokinetics
- WADA Status: Prohibited at all times (S1 Anabolic Agents)
🧬 Mechanism of Action
Androgen Receptor Binding
Nandrolone phenylpropionate is hydrolysed to free nandrolone after injection. Nandrolone binds the androgen receptor (AR), initiating transcription of genes involved in protein synthesis, nitrogen retention, muscle hypertrophy, and erythropoiesis.
Reduced Aromatisation & 5-α Reduction
Compared with testosterone, nandrolone aromatises less and is reduced to a weaker androgen (DHN), influencing androgenic outcomes in tissues such as the prostate, skin, and scalp.
Metabolic & Hematologic Effects
Nandrolone influences lipid metabolism, bone turnover, glucose handling, and red-blood-cell production—contributing to its use in hematology and osteoporosis research.
📚 Research Overview
| Research Area | Typical Findings |
|---|---|
| Muscle wasting & cachexia | Improved lean mass, strength, and nitrogen balance; endocrine suppression as a trade-off. |
| Bone density | Increased BMD and improved collagen structure in glucocorticoid-induced models. |
| Erythropoiesis | Elevated hemoglobin/hematocrit via EPO stimulation. |
| HPG-axis impact | Suppressed LH, FSH, and endogenous testosterone with dose-dependent recovery delays. |
| Cardiometabolic markers | Reduced HDL, increased LDL, blood pressure changes in longer-term exposure models. |
These outcomes are observed in clinical and preclinical research; not recommendations for human enhancement.
💡 Potential Research-Level Applications
- Lean mass and skeletal muscle anabolism models
- Joint and connective-tissue research (collagen, tendon, cartilage)
- Bone-density and osteoporosis exploration
- Hematology and erythropoietic studies
- Short-ester pharmacokinetic modeling
Applies only to controlled laboratory environments.
⚠️ Known Side Effects & Safety Considerations
- Endocrine suppression: LH/FSH inhibition, lowered natural testosterone, infertility in male models
- Cardiovascular: Decreased HDL, increased LDL, BP elevations, thrombosis risk
- Hepatic/Renal: Possible liver enzyme elevation; renal strain at high exposure
- Androgenic: Acne, oily skin, hair loss, virilisation effects in females
- Estrogenic & Progestogenic: Potential water retention or gynecomastia mechanisms
- Neuropsychiatric: Mood changes, irritability, libido changes
These effects are identified in AAS research literature and do nicht serve as guidance for human administration.
🛑 Compliance & Legal Status
- Classified as an anabolic agent under WADA S1 — prohibited at all times.
- Controlled/prescription-only substance in many jurisdictions (EU/UK/US).
- Supplied strictly as a research chemical by Royal Pharmaceuticals.
- Not approved by EMA, MHRA, FDA, or similar authorities.
📊 Technical Specifications
| Parameter | Value |
|---|---|
| Product Name | Nandro F 150 mg/ml |
| Marke | Königliche Pharmazeutika |
| Active Ester | Nandrolone Phenylpropionate |
| Concentration | 150 mg/ml |
| Ampoule Volume | 1 ml |
| Total Active per Pack | 1,500 mg (10 × 1 ml) |
| Research Route | Intramuscular (I.M.) – research only |
| Origin | United Kingdom |
| Analytical Interest | Anabolic index, ester kinetics, AR signaling, nitrogen balance, bone density, erythropoiesis |
| Storage | Cool, dry, light-protected environment |
For laboratory use only. Not for human or veterinary administration.
There are no reviews yet.
